~ Buy the POSIMIR (bupivacaine) Drug Profile, 2024 PDF Report in the Report Store ~

POSIMIR Drug Patent Profile

✉ Email this page to a colleague

When do Posimir patents expire, and what generic alternatives are available?

Posimir is a drug marketed by Innocoll and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-one patent family members in twenty-nine countries.

The generic ingredient in POSIMIR is bupivacaine. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bupivacaine profile page.

DrugPatentWatch^® Generic Entry Outlook for Posimir

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for POSIMIR?
What are the global sales for POSIMIR?
What is Average Wholesale Price for POSIMIR?

Summary for POSIMIR

International Patents:	61
US Patents:	6
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	125
Patent Applications:	4,352
What excipients (inactive ingredients) are in POSIMIR?	POSIMIR excipients list
DailyMed Link:	POSIMIR at DailyMed

Drug patent expirations by year for POSIMIR

US Patents and Regulatory Information for POSIMIR

POSIMIR is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting POSIMIR

Sustained release drug delivery systems with reduced impurities and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TO PRODUCE POST-SURGICAL ANALGESIA

Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS

FDA Regulatory Exclusivity protecting POSIMIR

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Innocoll	POSIMIR	bupivacaine	SOLUTION;INFILTRATION	204803-001	Feb 1, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for POSIMIR

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pacira Ireland Limited	Exparel liposomal	bupivacaine	EMEA/H/C/004586 Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.	Authorised	no	no	no	2020-11-16
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for POSIMIR

When does loss-of-exclusivity occur for POSIMIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Brazil

Patent: 2022013784
Patent: SISTEMAS DE DISTRIBUIÇÃO DE FÁRMACOS DE LIBERAÇÃO PROLONGADA COM IMPUREZAS REDUZIDAS E MÉTODOS RELACIONADOS
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 67217
Patent: SYSTEMES D'ADMINISTRATION DE MEDICAMENT A LIBERATION PROLONGEE AVEC IMPURETES REDUITES ET PROCEDES ASSOCIES (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS)
Estimated Expiration: ⤷ Sign Up

China

Patent: 5666621
Patent: 具有减少的杂质的持续释放药物递送系统及相关方法 (Sustained release drug delivery systems with reduced impurities and related methods)
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 90353
Patent: SYSTÈMES D'ADMINISTRATION DE MÉDICAMENT À LIBÉRATION PROLONGÉE AVEC IMPURETÉS RÉDUITES ET PROCÉDÉS ASSOCIÉS (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 23515918
Patent: 不純物が低減された徐放性薬物送達システム及び関連の方法
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 220140711
Patent: 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering POSIMIR around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006033948		⤷ Sign Up
Georgia, Republic of	P20094831	CONTROL RELEASE SYSTEM	⤷ Sign Up
European Patent Office	2415484	Composition anesthésique locale prolongée contenant du SAIB (Sustained local anesthetic composition containing SAIB)	⤷ Sign Up
Portugal	2415484		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration